Vtv Therapeutics Inc's Comment on Sales, Marketing and Customers
The company's collaboration revenue for the years ended December 31, 2025, 2024, and 2023 primarily derives from licenses of compounds in preclinical or clinical development stages. Key agreements include the Huadong License Agreement, which was terminated effective September 1, 2024, and the Newsoara License Agreement. Revenue is recognized upon achievement of development milestones. The company operates in the biopharmaceutical sector, with products regulated by government authorities in the United States and other jurisdictions, including the European Union. The regulatory process encompasses preclinical testing, submission of an Investigational New Drug Application (IND), approval by institutional review boards (IRB), clinical trials, and submission of a New Drug Application (NDA).
: vTv Therapeutics, a clinical-stage pharmaceutical company, has released its financial results for the fourth quarter and full year of 2024. The announcement highlights strategic corporate advancements alongside significant clinical developments, including the lifting of a clinical hold for their late-stage cadisegliatin program for diabetes. This article examines the implications of these updates for the future of diabetes treatment and the potential impacts on vTv s financial and corporate trajectory. Diabetes remains one of the most challenging chronic diseases affecting millions globally. Innovative treatments and drugs are crucial in augmenting existing therapeutic modalities. In this context, vTv T...
Vtv Therapeutics Inc’s Comment on Sales, Marketing and Customers
The company's collaboration revenue for the years ended December 31, 2025, 2024, and 2023 primarily derives from licenses of compounds in preclinical or clinical development stages. Key agreements include the Huadong License Agreement, which was terminated effective September 1, 2024, and the Newsoara License Agreement. Revenue is recognized upon achievement of development milestones. The company operates in the biopharmaceutical sector, with products regulated by government authorities in the United States and other jurisdictions, including the European Union. The regulatory process encompasses preclinical testing, submission of an Investigational New Drug Application (IND), approval by institutional review boards (IRB), clinical trials, and submission of a New Drug Application (NDA).
Sources:
Vtv Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Vtv Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Vtv Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
